Phosphate control in peritoneal dialysis

Contributions to Nephrology

Volumn 178, Issue , 2012, Pages 116-123

  Cozzolino, Mario ^a   Stucchi, Andrea ^a   Rizzo, Maria Antonietta ^a   Brenna, Irene ^a   Elli, Francesca ^a   Ciceri, Paola ^a   Bover, Jordi ^b   Cusi, Daniele ^a   Gallieni, Maurizio ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FUNDACIÓ PUIGVERT   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862115438     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000337831     Document Type: Article

References (48)

1. Melamed ML, Eustace JA, Plantinga L, Jaar BG, Fink NE, Coresh J, Klag MJ, Powe NR: Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006;70:351- 357.
2. Cozzolino M, Brancaccio D, Gallieni M, Slatoposlky E: Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005;68:429- 436.
3. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000;87: E10- 17.
4. Ciceri P, Volpi E, Brenna I, Arnaboldi L, Neri L, Brancaccio D, Cozzolino M: Combined effects of ascorbic acid and phosphate on rat VSMC osteoblastic differentiation. Nephrol Dial Transplant 2012;27:122- 127.
5. Kidney Disease: Improving Global Outcomes (KDIGO) CKD- MBD Work Group. Kidney Int Suppl 2009;113:S1-S130.
6. Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245- 252.
7. Tonelli M, Pannu N, Manns B: Oral phosphate binders in patients with kidney failure. N Engl J Med 2010;362:1312- 1324.
8. Cozzolino M, Gallieni M, Chiarelli G, Brancaccio D: Calcium and phosphate handling in peritoneal dialysis. Contrib Nephrol. Basel, Karger, 2006, vol 150, pp 214- 225.
9. Schmitt CP, Schaefer F, Huber D, et al: 1, 25(OH)2- vitamin D3 reduces spontaneous and hypocalcemia- stimulated pulsatile component of parathyroid hormone secretion. J Am Soc Nephrol 1998;9:54-62.
10. Cozzolino M, Brancaccio D, Gallieni M, et al: Pathogenesis of parathyroid hyperplasia in renal failure. J Nephrol 2005;18:5-8.
11. Denda M, Finch J, Slatopolsky E: Phosphorus accelerated the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis 1996;28:596-602.
12. Moe SM: Management of renal osteodystrophy in peritoneal dialysis patients. Perit Dial Int 2004;24:209- 216.
13. Kurz P, Tsobanelis T, Roth P, et al: Differences in calcium kinetic pattern between CAPD and HD patients. Clin Nephrol 1995;44:255-261.
14. Sanchez C, Lopez-Barea F, Sanchez-Cabezudo J, Bajo A, Mate A, Martinez E, Selgas R, Collaborators of the Multicentre Study Group: Low vs. standard calcium dialysate in peritoneal dialysis: differences in treatment, biochemistry and bone histomorphometry. A randomized multicentre study. Nephrol Dial Transplant 2004;19:1587-1593.
15. Gallieni M, Borgatti P, Bottalico D, et al: Mineral metabolism in 490 peritoneal dialysis patients: The ROCK- PD (Renal Osteodystrophy and Calcifications: Key Factors in Peritoneal Dialysis) Multicenter Study. J Am Soc Nephrol 2005;16:456A.
16. Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT, Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) Study Group: The kidney disease outcomes quality initiative (K/DOQI) guideline for bone metabolism and disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis 2005;46:925-932.
17. Ketteler M: The control of hyperphosphatemia in chronic kidney disease: which phosphate binders? Int J Artif Organs 2009;32:95- 100.
18. Kalantar-Zadeh K, Gutekunst L, Mehrotra R, et al: Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol 2010;5:519- 530.
19. Botelho C, Rodrigues A, Santos O: Phosphate removal in peritoneal dialysis regimens: an underestimated adequacy parameter. NDT Plus 2010;33(suppl 3):477- 478.
20. Cozzolino M, Galassi A, Gallieni M, Brancaccio D: Preventive measures and new pharmacological approaches of calcium and phosphate disorders. Contrib Nephrol. Basel, Karger, 2008, vol 161, pp 234- 239.
21. Cozzolino M, Mazzaferro S, Brandenburg V: The treatment of hyperphosphataemia in CKD: calcium- based or calcium- free phosphate binders? Nephrol Dial Transplant 2011;26:402- 407.
22. Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz- Buxo JA, CARE- 2 Investigators: A 1- year randomized trial of calcium acetate versus Sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation- 2 (CARE- 2) study. Am J Kidney Dis 2008;51:952- 965.
23. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM: Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71:438- 441.
24. Suki WN, Zabaneh R, Cangiano JL, et al: Effects of Sevelamer and calciumbased phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130- 1137.
25. St. Peter WL, Liu J, Weinhandl E, Fan Q: A comparison of Sevelamer and calcium- based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 2008;51:445- 454.
26. Di Iorio B, Bellasi A, Russo D, on behalf of the INDEPENDENT Study Investigators: Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 2012;7:487- 493.
27. Raggi P, Vukicevic S, Moyse's R M, Wesseling K, Spiegel DM: Ten- year experience with Sevelamer and calcium salts as phosphate binders. Clin J Am Soc Nephrol 2010;5(suppl 1): S31-S40.
28. Slatopolsky EA, Burke SK, Dillon MA: RenaGel, a nonabsorbed calcium- and aluminium- free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int 1999;55:299- 307.
29. Evenepoel P, Selgas R, Caputo F, et al: Efficacy and safety of Sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. Nephrol Dial Transplant 2009;24:278-285.
30. Soroka SD, Beard KM, Mendelssohn DC, Cournoyer SH, Da Roza GA, Geary DF: Mineral metabolism management in Canadian peritoneal dialysis patients. Clin Nephrol 2011;75:410- 415.
31. Pagé D, Knoll G: Peritoneal dialysis patients using Sevelamer do not present the acidosis problems that hemodialysis patients do. Adv Periton Dial 2005;21:185- 187.
32. Singharetnam W, Holley JL: Acute treatment of constipation may lead to transmural migration of bacteria resulting in Gram- negative, polymicrobial, or fungal peritonitis. Perit Dial Int 1996;16:423-425.
33. Bender FH, Bernardini J, Piraino B: Prevention of infectious complications in peritoneal dialysis: best demonstrated practices. Kidney Int 2006;103:S44-54.
34. Kerschbaum J, Konig P, Hausdorfer J, Mayer G, Rudnicki M: Sevelamer use and incidence of peritonitis in peritoneal dialysis. Wien Klin Wochenschr 2011;123:204- 208.
35. Chertow GM, Burke SK, Dillon MA, Slatopolsky E: Long- term effects of Sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999;14:2907-2914.
36. Ramos R, Moreso F, Borras M, et al: Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross- sectional study. Perit Dial Int 2007;27:697-701.
37. Delmez J, Block G, Robertson J, et al: A randomized, double- blind, crossover design study of Sevelamer hydrochloride and Sevelamer carbonate in patients on hemodialysis. Clin Nephrol 2007;68:386-391.
38. Ketteler M, Rix M, Fan S, et al: Efficacy and tolerability of Sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol 2008;3:1125-1130.
39. Pai AB, Shepler BM: Comparison of Sevelamer hydrochloride and Sevelamer carbonate: risk of metabolic acidosis and clinical implications. Pharmacotherapy 2009;29: 554- 561.
40. Pennick M, Damment SJP, Gill M: The pharmacokinetics and tissue distribution of lanthanum carbonate (Fosrenol®) a novel non- aluminium, non- calcium phosphate binder. Poster 36th Ann Meet Am Soc Nephrology, San Diego, 2003.
41. Albaaj F, Hutchison AJ: Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients. Expert Opin Pharmacother 2005;6:319-28.
42. Lacour B, Lucas A, Auchèere D, Ruellan N, de Serre Patey NM, Drüeke TB: Chronic renal failure is associated with increased tissue deposition of lanthanum after 28- day oral administration. Kidney Int 2005;67:1062- 1069.
43. Hutchison A: Analysis of liver function and hepatobiliary adverse event data from 2000 dialysis patients participating in clinical trials on the new phosphate binder, lanthanum carbonate. Nephrol Dial Transplant 2005;20(suppl 5):V93.
44. Finn WF, Joy MS, LAM- 308 Study Group: A long-term, open- label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis. Curr Med Res Opin 2005;21:657- 664.
45. Vemuri N, Michelis MF, Matalon A: Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter openlabel study. BMC Nephrol 2011;12:49.
46. D'Haese, PC, Spasovski GB, Sikole A, et al: A multicenter study on the effects of lanthanum carbonate (FosrenolTM) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003;63:S73- S78.
47. Malluche HH, Faugere M- C, Wang G, et al: No evidence of osteomalacia in dialysis patients treated with lanthanum carbonate up to 5 years. J Am Soc Nephrol 2004;15:270A.
48. Kawanishi H, Ishida M, Ishizaki M, Takuma Y, Tamura H, Kobayashi S, Tamura T, Ohashi H, Hiramatsu M, Minakuchi J, Hirakata H, Shigematsu T: Lanthanum Carbonate treatment of patients with hyperphosphatemia undergoing CAPD. Perit Dial Int 2008;28:673-682.